One of the most conceptually striking studies targets the tumor microenvironment itself. Researchers developed and evaluated a PET imaging approach aimed at CD163, a surface marker carried by tumor-associated macrophages, the immune cells that tumors frequently recruit and reprogram to support their own growth. In head and neck squamous cell carcinoma, a malignancy in which the immune landscape often determines how patients respond to therapy, a tracer labeled with copper-64, known as 64Cu-ICT-01, allowed investigators to visualize where these macrophages reside and how their distribution shifts during tumor progression and after treatment. Complementary testing on human tissue confirmed that the tracer binds specifically to CD163, supporting its translational relevance. If validated further, the technique could give oncologists a noninvasive window into immunosuppressive niches within tumors, potentially helping predict which patients will benefit from immunotherapy long before changes in tumor size become apparent.

Theranostics, the pairing of diagnostic imaging with targeted radionuclide therapy, features prominently in the new research. A prospective clinical trial evaluated 177Lu-LNC1010, a long-acting somatostatin analog labeled with lutetium-177, for peptide receptor radionuclide therapy in 22 patients with progressive metastatic neuroendocrine tumors. Long-acting formulations are designed to prolong tumor exposure to the therapeutic radiation while simplifying treatment logistics, and in this trial patients received up to four cycles. The investigators systematically assessed safety, tumor response, absorbed radiation doses delivered to tumors and organs at risk, progression-free survival and overall survival during follow-up. The results add to rapidly growing evidence that radioligand therapy can deliver clinically meaningful disease control in neuroendocrine tumors, a class of cancers that has historically been difficult to treat with conventional chemotherapy.

A second radiopharmaceutical study turned its attention to CEACAM5, a cell-surface protein overexpressed in several cancers, including colorectal cancer, and an established target for both antibody-drug conjugates and radioligand therapy. In laboratory and mouse experiments, a radiolabeled compound designed to bind CEACAM5 selectively attached to CEACAM5-positive cancer cells while demonstrating favorable tumor uptake and reduced accumulation in the kidneys, a critical safety consideration for peptide- and antibody-based radionuclide therapies. Remarkably, a single treatment significantly extended survival in mice bearing CEACAM5-positive tumors, with only mild and temporary toxicity observed. The findings position this agent as a candidate for translation into first-in-human trials and reinforce the broader trend of matching radiopharmaceuticals to molecular signatures rather than tumor locations.

Pediatric oncology also gained a potential new target. Neuroblastoma, an aggressive cancer of the sympathetic nervous system that primarily affects young children, remains one of the most challenging malignancies to image and treat. Researchers examined DLL3, a protein better known from small cell lung cancer, as a candidate target in neuroblastoma. Analysis of human tumor samples and preclinical models revealed that DLL3 is widely expressed and frequently localized on the cell surface, an essential prerequisite for both imaging agents and therapeutic radioligands. DLL3-targeted PET imaging subsequently demonstrated tumor-specific uptake not only in preclinical models but also in four patients with relapsed neuroblastoma, offering early clinical proof of concept. For children with few remaining options, a validated DLL3 pathway could open the door to both molecular imaging and precision radioligand therapy in the future.

Beyond theranostics, several new studies interrogate the reliability of the workhorse technology of molecular imaging itself. Amyloid PET, used to detect the amyloid plaques characteristic of Alzheimer’s disease, has become central to diagnosis and to the growing field of disease-modifying Alzheimer’s therapy. A study of nearly 1,500 amyloid PET scans compared interpretations by local radiologists and nuclear medicine physicians with those of expert readers across three FDA-approved tracers. The good news: agreement was consistently strong, with similar performance for positive and negative scans. Importantly, the study also found that lower reader confidence was associated with reduced agreement, suggesting that confidence ratings could serve as a quality-control signal in routine practice. As amyloid PET demand surges worldwide, the findings provide reassurance that community-based interpretation can keep pace with expert standards.

Prostate cancer, the most active arena in nuclear medicine today, received an unusually detailed quantitative treatment. In a multicenter study, researchers evaluated measurements derived from 18F-piflufolastat PSMA PET/CT, matching PET findings with histopathology from 305 men to determine which imaging metrics best distinguish malignant prostate cancer from benign tissue. Several quantitative measures correlated with malignancy, but the SUVmax-to-blood-pool ratio showed the strongest ability to separate cancerous from benign lesions, both within the prostate and at metastatic sites. Establishing such thresholds is a critical step toward standardizing PSMA PET interpretation, reducing unnecessary biopsies, and enabling radiologists to report results with quantitative, reproducible criteria rather than subjective visual assessment alone.

Combination therapy, meanwhile, may soon be guided by a simple blood test and a PET scan. In an analysis of 37 patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617 together with pembrolizumab, an immune checkpoint inhibitor, researchers examined whether baseline biomarkers could predict response. Patients with lower levels of circulating tumor DNA at the start of treatment and higher PSMA uptake on PET fared better, while changes in circulating tumor DNA and PSMA PET measurements at 12 weeks reflected both the depth and durability of response. The study points toward a practical biomarker strategy for selecting patients for combined radioligand immunotherapy, one of the most closely watched approaches in advanced prostate cancer.

Breast and kidney cancer imaging rounded out the new research portfolio. In triple-negative breast cancer, the most aggressive breast cancer subtype, a study compared 18F-ATD001, a PARP-targeted PET tracer, with standard 18F-FDG PET/CT in 37 women. The two methods detected similar numbers of lesions, and although the PARP tracer showed lower overall uptake, its signal correlated moderately with FDG in primary tumors, suggesting it may provide complementary biological information about DNA repair enzyme expression that FDG cannot capture. Separately, a prospective study of 68Ga-DPI-4452, a tracer targeting carbonic anhydrase IX, evaluated 30 adults with suspected kidney tumors. The agent identified clear cell renal cell carcinoma with high sensitivity and detected substantially more metastatic lesions than conventional imaging, with tracer uptake strongly correlating with CAIX expression in tumor tissue, a combination of diagnostic accuracy and biological validation that could reshape renal cancer imaging.

Taken together, the ahead-of-print collection paints a picture of a field in confident ascent. Tracers are becoming more biologically specific, imaging metrics are being quantified against gold-standard pathology, and therapy is increasingly delivered by molecules that home in on cancer cells while sparing healthy tissue. From macrophage mapping in head and neck cancer to DLL3 imaging in children with relapsed neuroblastoma, the studies collectively advance the central promise of nuclear medicine and theranostics: diagnosing and treating each patient according to the unique molecular fingerprint of their disease, with the goal of achieving the best possible outcomes.

Subject of Research: Advances in molecular imaging and radiopharmaceutical therapy reported in The Journal of Nuclear Medicine ahead-of-print research

Article Title: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026

Article References: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nuclear medicine, PET imaging, theranostics, radiopharmaceutical therapy, PSMA PET, neuroendocrine tumors, neuroblastoma, amyloid PET, prostate cancer, triple-negative breast cancer, kidney cancer, tumor-associated macrophages

Published in The Lancet on Aug. 6, the findings could reshape treatment for patients whose cancer has recently spread and has received little or no prior systemic therapy. The results supported the U.S. Food and Drug Administration’s approval in late July of lutetium Lu-177 vipivotide tetraxetan, also known as ^177Lu-PSMA-617, for earlier use alongside an androgen receptor pathway inhibitor and androgen deprivation therapy.

Metastatic prostate cancer is commonly driven by male sex hormones, particularly testosterone and related androgens. For that reason, the standard treatment backbone has typically combined androgen deprivation therapy, which suppresses the body’s production of testosterone, with an androgen receptor pathway inhibitor, which blocks cancer cells from responding to residual hormonal signals. Although this approach can control disease for a time, resistance eventually develops in many patients. The PSMAddition trial tested whether introducing a targeted radiopharmaceutical before resistance emerges could extend that period of control.

The study enrolled more than 1,100 men with PSMA-positive metastatic prostate cancer at 169 sites in 20 countries. Approximately half received intravenous ^177Lu-PSMA-617 every six weeks in addition to androgen deprivation therapy and an androgen receptor pathway inhibitor. The other participants received the hormonal treatment combination alone, representing the previous standard of care. Patients in the control group were permitted to cross over to the three-drug regimen if their disease progressed, a design that allowed them access to the investigational treatment while preserving the trial’s ability to compare initial treatment strategies.

The radiopharmaceutical works through a molecular targeting system. PSMA is a protein found at high levels on the surface of most prostate cancer cells; according to the investigators, roughly nine in ten patients with metastatic prostate cancer have PSMA-positive tumors. ^177Lu-PSMA-617 consists of a PSMA-binding molecule chemically linked to lutetium-177, a radioactive isotope. After the drug binds to PSMA, it is taken toward or into the tumor cell, where the isotope emits beta radiation. This radiation damages nearby cellular DNA, helping destroy malignant cells while limiting exposure to tissues that carry little or no PSMA.

The trial’s primary result was radiographic progression-free survival, which measures how long patients live without visible growth or spread of cancer on imaging or death from any cause. Early addition of ^177Lu-PSMA-617 extended this interval compared with hormonal treatment alone. The investigators also reported that the drug delayed the development of castration-resistant disease, the stage at which prostate cancer continues progressing despite testosterone suppression. In addition, patients receiving the targeted radiotherapy experienced a longer interval before cancer-related symptoms involving the skeleton appeared.

Bone complications are a major concern in advanced prostate cancer because the disease frequently spreads to the skeleton. Tumors in bone can cause pain, fractures, spinal cord compression and other disabling problems. By delaying skeletal symptoms, the treatment may preserve quality of life as well as postpone the need for subsequent therapies. However, the researchers emphasized that longer follow-up is still needed to determine whether the early progression benefit will translate into a statistically confirmed improvement in overall survival.

The added treatment also brought additional side effects, as expected from a three-drug regimen that combines hormonal therapy with systemic radiation. Dry mouth was the most frequently reported adverse event, affecting 46% of patients who received ^177Lu-PSMA-617. The symptom occurs because salivary glands can express PSMA and may absorb some of the radiopharmaceutical. Fatigue was also common, reflecting the effects of both radiation and hormonal treatment. Physicians must weigh these risks against the potential benefit and monitor patients over time for less common or delayed complications.

The therapy is not suitable for every person with metastatic prostate cancer. Patients must first undergo specialized molecular imaging to confirm that their tumors contain sufficient PSMA for targeting. Administration requires nuclear medicine physicians or radiation oncologists, as well as facilities equipped to handle radioactive medicines. Treatment centers must also provide guidance on radiation safety, including precautions designed to reduce exposure to family members and others in the household. These requirements may make access more difficult for patients who live far from academic medical centers or specialized oncology programs.

The early success of ^177Lu-PSMA-617 follows earlier studies showing activity in patients whose metastatic prostate cancer had already become resistant to hormonal treatment. Its use at diagnosis represents a shift in strategy: rather than reserving targeted radiotherapy for advanced, treatment-resistant disease, clinicians may now deploy it while tumors remain more vulnerable to combined treatment. The PSMAddition investigators are continuing to analyze long-term survival and safety data. As additional molecular imaging agents and biomarker-driven therapies enter clinical practice, treatment selection is likely to become increasingly individualized, with the biology of each tumor helping determine which targeted drug is introduced, and when.

Subject of Research: Early use of targeted radionuclide therapy with ^177Lu-PSMA-617 in PSMA-positive metastatic prostate cancer.

News Publication Date: 6-Aug-2026

Web References: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy; https://news.weill.cornell.edu/news/2017/05/first-clinical-trial-of-new-targeted-molecular-therapy-in-us-takes-aim-at-incurable

References: The Lancet; PSMAddition phase 3 clinical trial.

Keywords: Prostate cancer, metastatic prostate cancer, PSMA, ^177Lu-PSMA-617, lutetium vipivotide tetraxetan, targeted radionuclide therapy, radiopharmaceuticals, androgen deprivation therapy, androgen receptor pathway inhibitors, cancer treatment

Prostate cancer, when recurrent and metastatic, poses substantial therapeutic challenges, particularly when cancer cells colonize only a few distinct sites distant from the primary tumor. In the oligometastatic state, characterized by up to five metastatic lesions, high-precision radiation modalities like SBRT have become increasingly prevalent. SBRT permits the administration of ablation-dose radiation with pinpoint accuracy, targeting tumors while sparing healthy tissue. However, microscopic disease that eludes even state-of-the-art imaging has remained a critical barrier, often precipitating relapse despite local control.

The LUNAR trial’s innovation lies in synergistically combining SBRT with a radiopharmaceutical agent, ^177Lu-PNT2002, which homes in on prostate-specific membrane antigen (PSMA) expressed abundantly on prostate cancer cells. This radioligand therapy delivers targeted beta particle emissions directly to cancer cells throughout the body, addressing both visible and occult metastases. Until now, such radiopharmaceuticals were mainly deployed in advanced, late-stage disease. LUNAR investigated their potential as a neoadjuvant treatment in earlier metastatic phases, in conjunction with precise metastasis-directed radiation.

Ninety-two men with hormone-sensitive oligometastatic prostate cancer were randomly allocated to receive either SBRT alone or the investigational radiopharmaceutical followed by SBRT. Patients had one to five metastatic lesions confirmed via PSMA PET/CT, an imaging modality delivering unprecedented sensitivity and tumor detection accuracy. Follow-up involved meticulous biochemical (PSA level) monitoring and scheduled imaging to assess disease progression.

Remarkably, patients receiving the combination of ^177Lu-PNT2002 and SBRT exhibited a median progression-free survival of 18 months, more than doubling the seven months observed in the SBRT-only cohort. The statistical significance (p<0.001) reinforces the robust efficacy of this integrated approach. The enhanced therapeutic impact endured even after controlling for baseline PSA, hormonal therapy history, and lesion count, underscoring the radiopharmaceutical’s role as an independent contributor to improved outcomes.

A profoundly consequential finding was the substantial delay in initiation of androgen deprivation therapy (ADT) among patients treated with the combination regimen. ADT, while standard in recurrent prostate cancer, is associated with debilitating side effects including fatigue, osteoporosis, metabolic disturbances, and cardiovascular risks. Patients on the novel therapy deferred ADT for an average of 24 months, compared to 14 months for those receiving radiation alone, potentially translating to enhanced quality of life and reduced treatment-related morbidity.

Assessment of PSA responses further elucidated therapeutic benefits; 52% of patients in the combination arm achieved a PSA reduction of 50% or greater, compared to 31% in the SBRT-only group. Such biochemical responses portend durable clinical benefits and reinforce the synergy achieved by integrating systemic radiopharmaceutical therapy with localized radiation.

Crucially, the local control rates attained through SBRT were extraordinarily high—98% for radiation alone and a perfect 100% with the addition of ^177Lu-PNT2002—indicating undercurrent microscopic disease driving progression rather than failure at previously treated sites. Indeed, 98% of progression events represented new metastatic growths, highlighting the critical need for systemic treatment strategies to complement radiation.

Safety profiles between treatment arms were comparable, with no significant increase in severe adverse events seen upon addition of the radiopharmaceutical. Grade 3 toxicities were largely confined to transient leukopenia, affecting only a small minority of patients across both arms. This favorable tolerability underscores the clinical feasibility of employing radioligand therapy in earlier disease stages without incurring prohibitive toxicity.

The LUNAR trial thus positions ^177Lu-PNT2002-mediated radiopharmaceutical therapy as a promising adjunct to definitive radiation in oligometastatic prostate cancer, delivering a dual assault on both apparent and occult disease compartments. This approach could redefine standards of care, shifting paradigms from sequential therapies to integrated multimodal regimens that maximize disease control while preserving patient well-being.

Notably, prior investigations employing radiopharmaceuticals targeting bone metastases exclusively have not demonstrated similar benefits, emphasizing the importance of PSMA-targeting agents that directly engage tumor cells irrespective of location. This nuanced understanding differentiates LUNAR’s approach and offers plausible mechanistic insights into improved outcomes.

Despite these advances, the challenge of residual microscopic disease remains unresolved, as 64% of combination therapy recipients eventually experienced progression. This limitation highlights the necessity for continued research refining dosing strategies, treatment sequencing, and developing next-generation agents with enhanced tumor selectivity and radiobiologic potency.

Currently, ^177Lu-PNT2002 remains investigational for oligometastatic recurrent prostate cancer, accessible only within clinical trials. However, both SBRT and PSMA PET/CT are FDA-approved and increasingly integrated in clinical practice, paving a practical path toward wider adoption of combined modality therapies pending regulatory approvals and further validation.

In conclusion, the LUNAR study heralds a paradigm shift in treating oligometastatic prostate cancer by demonstrating that neoadjuvant PSMA-targeted radiopharmaceuticals significantly enhance radiation efficacy, prolong progression-free survival, and meaningfully delay systemic hormonal therapy. As mechanistic insights deepen and clinical protocols refine, this integrated therapeutic avenue holds great promise to improve patient outcomes in a disease historically marked by complex recurrence dynamics.

Subject of Research:
Oligometastatic recurrent prostate cancer; radiopharmaceutical and radiation therapy combination

Article Title:
Novel Radiopharmaceutical Plus Radiation Therapy Significantly Extends Progression-Free Survival in Oligometastatic Prostate Cancer: Insights from the Phase II LUNAR Trial

News Publication Date:
September 28, 2025

Web References:

• ASTRO Annual Meeting 2025
• LUNAR Abstract
• Related ASCO Publication

References:
Data and results presented at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting, reported by Dr. Amar U. Kishan and colleagues.

Keywords:
Prostate cancer, oligometastatic disease, radiopharmaceutical therapy, ^177Lu-PNT2002, PSMA-targeted therapy, stereotactic body radiation therapy (SBRT), progression-free survival, androgen deprivation therapy, metastasis-directed therapy, clinical trial, precision oncology

In the context of a rapidly evolving oncology landscape, Davis’s appointment introduces a visionary leadership approach to ASTRO’s business growth and partnership strategy. Charged with developing robust collaborations across public and private sectors, her leadership will be instrumental in augmenting the Society’s capabilities to translate scientific breakthroughs into tangible improvements in patient outcomes. By fostering synergistic alliances, ASTRO aims to expedite innovation adoption and amplify the reach of radiation therapy modalities worldwide.

One of Davis’s primary objectives involves bolstering ASTRO’s multifaceted portfolio of initiatives that emphasize precision medicine and advanced therapeutic techniques. These include spearheading efforts in programs such as the Radiopharmaceutical Therapy (RPT) Roundtable, which concentrates on the integration and clinical application of radiopharmaceuticals—an emerging pillar in targeted cancer treatment. The RPT Roundtable convenes experts to evaluate the efficacy and safety of novel radionuclide therapies, providing a platform that accelerates translational research and standardizes clinical practice protocols.

Further solidifying ASTRO’s commitment to scientific excellence, Davis will shepherd the Scientific Challenges Program—an initiative designed to address critical unanswered questions that impede progress in radiation oncology. This program brings together interdisciplinary teams to dissect complex biological mechanisms, optimize radiation delivery, and refine therapeutic indices. By targeting these scientific impediments, ASTRO fosters a culture of innovation that propels the discipline toward new paradigms of personalized cancer care.

Additionally, Davis’s role encompasses enhancing patient-centered resources such as the Partners in Patient Education (PiPE) program. This endeavor focuses on democratizing access to reliable, evidence-based information about radiation therapies, thus empowering patients and caregivers with knowledge essential for informed decision-making. The educational outreach of PiPE integrates multimedia tools and community engagement strategies, positioning ASTRO as a conduit between cutting-edge research and public awareness.

Karen Davis brings a formidable blend of nonprofit leadership and strategic development expertise accumulated over more than three decades, bridging organizational growth with mission-driven objectives. Prior to her tenure at ASTRO, she served as Chief Development and External Affairs Officer at the National Council on Aging (NCOA), where she excelled in crafting initiatives that mobilized resources and forged impactful partnerships to benefit vulnerable populations. Her proficiency in orchestrating large-scale campaigns and navigating complex funding landscapes positions her uniquely to elevate ASTRO’s endeavors.

Davis’s earlier career trajectory includes senior leadership roles at the Student Conservation Association and the National Park Foundation, underlining her capacity to helm diverse organizations and generate transformative outcomes. Her consultancy experience with Changing Our World, Inc. provided her with a nuanced understanding of philanthropic mechanisms and public-sector collaborations, essential tools for scaling ASTRO’s ambitions.

Vivek S. Kavadi, MD, MBA, FASTRO, ASTRO’s Chief Executive Officer, emphasized the strategic importance of this appointment, highlighting Davis’s capability to catalyze the Society’s mission. Dr. Kavadi noted, “Karen’s expertise in building high-impact partnerships and mobilizing critical resources is vital to accelerating ASTRO’s initiatives aimed at enhancing cancer treatment worldwide. Her addition fortifies our leadership team and exemplifies our vision for sustainable growth aligned with scientific innovation.”

Under Davis’s stewardship, ASTRO is poised to deepen its engagement with emerging scientific disciplines, including molecular radiotherapy and immuno-radiation oncology, where the convergence of radiation and immunomodulation therapies promises to revolutionize treatment protocols. By capitalizing on evolving technologies and fostering interdisciplinary dialogues, ASTRO aims to guide clinical practice into a new era of efficacy and safety.

Moreover, ASTRO’s affiliation with the Radiation Oncology Institute (ROI), its dedicated research foundation, will benefit from Davis’s strategic insight, as she aligns fundraising efforts with cutting-edge research priorities. The ROI serves as a catalyst for investigator-initiated studies and pilot projects that lay the groundwork for transformative clinical trials, underpinning the future of radiation oncology.

Davis’s presence at ASTRO’s Arlington headquarters situates her at the junction of scientific discourse and policy advocacy, enabling real-time interaction with stakeholders ranging from researchers to healthcare policymakers. Her role as a nexus for communication underscores ASTRO’s holistic approach to expanding the use of radiation therapies, incorporating educational, clinical, and legislative dimensions.

As the global oncology community confronts the challenge of increasing cancer incidences and the imperative for accessible, effective treatments, ASTRO’s strategic investments in leadership and collaborative initiatives are critical. Davis’s appointment represents a concerted effort to bridge scientific innovation with practical implementation, thereby improving survival rates and quality of life for cancer patients around the world.

In an era marked by rapid advancements and the growing integration of technology in medicine, ASTRO under Davis’s business development and marketing leadership is set to navigate competitive landscapes, identify novel funding streams, and elevate the Society’s profile as an indispensable resource for healthcare professionals specializing in radiation oncology. This expansion of executive capabilities not only signals growth but also a renewed dedication to the mission of conquering cancer through enlightened radiation therapy.

Karen Davis expressed her enthusiasm, stating, “Joining ASTRO at this juncture is a tremendous privilege. I am excited to collaborate with an exceptional team devoted to advancing education and research that profoundly impact radiation oncology. Together, we aim to harness strategic partnerships and innovative marketing to extend ASTRO’s influence in transforming patient care globally.”

For those seeking to partner with ASTRO or support its expansive mission, detailed information is accessible through the organization’s official channels. The Society remains committed to transparency and collaborative progress, inviting stakeholders to join in its efforts to redefine the boundaries of cancer treatment.

ABOUT ASTRO
The American Society for Radiation Oncology (ASTRO) stands as the largest global society dedicated to radiation oncology, comprising over 10,000 members including physicians, nurses, biologists, physicists, radiation therapists, dosimetrists, and other allied healthcare professionals. Radiation therapy currently plays a critical role in curing approximately 40% of cancer cases worldwide, with more than one million patients in the United States receiving such treatments annually. Through its comprehensive programs, research initiatives, and educational outreach, ASTRO continues to pioneer advancements that elevate standards of care and foster hope for millions affected by cancer.

Subject of Research: Radiation Oncology, Radiopharmaceutical Therapy, Cancer Treatment Innovation
Article Title: ASTRO Strengthens Leadership to Accelerate Innovations in Radiation Oncology and Cancer Care
News Publication Date: June 18, 2025
Web References:

• Radiopharmaceutical Therapy (RPT) Roundtable: https://www.astro.org/provider-resources/radiopharmaceutical-therapy/radiopharmaceutical-roundtable
• Scientific Challenges Program: https://www.astro.org/provider-resources/research/scientific-challenges
• Partners in Patient Education (PiPE) Program: https://www.astro.org/provider-resources/shareable-resources/partners-in-patient-education
• Radiation Oncology Institute (ROI): http://www.roinstitute.org
• RTAnswers.org: http://www.rtanswers.org
• ASTRO Website: https://www.astro.org
• ASTRO Media Center: https://www.astro.org/News-and-Publications/News-and-Media-Center
• ASTRO Social Media: https://www.astro.org/About-ASTRO/Social-Media

Keywords: Radiation Oncology, Cancer Treatment, Scientific Organizations, Radiopharmaceutical Therapy, Medical Education, Oncology Research, Patient Care, Medical Innovation